logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Dietary Cholesterol Absorption Inhibitor class drugs

    FiltersReset Filters
    3 results

    • ezetimibe and simvastatin

      (Ezetimibe and Simvastatin)
      AvKARE
      Usage: Ezetimibe and simvastatin tablets are indicated as adjunct therapy to diet for reducing cholesterol and triglyceride levels in patients with primary or mixed hyperlipidemia, including homozygous familial hypercholesterolemia. They are part of a comprehensive approach to reduce the risk of atherosclerotic vascular disease.

    • nexlizet

      (Bempedoic Acid and Ezetimibe)
      Esperion Therapeutics, Inc.
      Usage: NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated as an adjunct to diet for reducing LDL-C in adults with primary hyperlipidemia, including HeFH. Bempedoic acid also lowers myocardial infarction and coronary revascularization risk in adults unable to take statins, with or without established cardiovascular disease.

    • zetia

      (Ezetimibe)
      Organon LLC
      Usage: ZETIA® is indicated for reducing elevated LDL-C in adults with primary hyperlipidemia and HeFH, in pediatric patients (10+ years) with HeFH, adults with mixed hyperlipidemia, and those with HoFH. It also reduces sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.